Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has shared an update.
Pharmaron Beijing Co., Ltd. has called its 2025 annual general meeting for June 12, 2026 in Beijing, where shareholders will review the 2025 board work report, profit distribution and 2026 interim dividend plan, the 2025 annual report, director remuneration and a new remuneration management policy. The agenda also includes approving the 2026 hedging quota, appointing domestic, internal control and international auditors, electing a new board including executive, non-executive and independent non-executive directors, and voting on external guarantee limits, a general issuance mandate, registered capital increase and amendments to the articles of association, signaling ongoing capital and governance adjustments aimed at supporting the company’s future operations and growth.
These resolutions collectively underscore Pharmaron’s efforts to refresh its board structure, formalize compensation and risk management frameworks, and secure flexibility for future financings. The proposed increase in registered capital and issuance mandate, together with updated governance documents, may provide the company with additional tools to fund expansion and strengthen its strategic positioning in the competitive contract research and development market.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based contract research, development and manufacturing organization serving the global pharmaceutical and biotech industry. The company provides integrated services spanning discovery, preclinical and clinical research, as well as drug development and manufacturing, with a focus on supporting innovative therapies for international customers.
Average Trading Volume: 6,007,989
Technical Sentiment Signal: Sell
Current Market Cap: HK$51.05B
For a thorough assessment of 3759 stock, go to TipRanks’ Stock Analysis page.